Liraglutide, semaglutide, and tirzepatide are all GLP-1 agonists resulting in significant weight loss in RCTs
Image Credit: Love Employee / Shutterstock In a recent study published in the International Journal of Obesity , researchers assessed the effects of glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists on weight and body composition in adults with overweight or obesity

Citations Citations to this article as recorded by Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches Prashant Tiwari, Istuti Saraswat, Jyoti Gupta Current Microbiology .2026;[Epub] CrossRef Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification Tai-Chung Tseng, Shang-Chin Huang, Jia-Horng Kao Hepatology Communications .2026;[Epub] CrossRef Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G
Nguyen, K., Dersnah, G